Verve Therapeutics Inc Cash Flow-to-Debt Ratio
Verve Therapeutics Inc cash flow-to-debt ratio. Verve Therapeutics Inc (VERV) has a Cash Flow-to-Debt Ratio of -0.20x as of March 2025, meaning its operating cash flow of $-27.84 Million could theoretically repay 0% of its total liabilities ($140.65 Million) in one year. See Verve Therapeutics Inc leverage flexibility ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Verve Therapeutics Inc (2019–2024)
Cash flow-to-debt ratio of Verve Therapeutics Inc from 2019 to 2024. Historical debt coverage capacity for Verve Therapeutics Inc across 6 annual periods. Also explore VERV year-over-year net asset growth to track the company's year-over-year net asset growth rate.
Verve Therapeutics Inc Cash Flow-to-Debt Ratio by Year (2019–2024)
Verve Therapeutics Inc cash flow-to-debt ratio by year from 2019 to 2024. Year-by-year debt coverage analysis for Verve Therapeutics Inc. For the full cash flow conversion analysis, see VERV operating cash flow.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -1.02x | $-157.69 Million | $153.99 Million | ▼ -4.9% |
| 2023 | -0.98x | $-149.55 Million | $153.19 Million | ▼ -2.4% |
| 2022 | -0.95x | $-122.33 Million | $128.29 Million | ▲ +67.2% |
| 2021 | -2.91x | $-77.88 Million | $26.77 Million | ▼ -1074.0% |
| 2020 | -0.25x | $-35.27 Million | $142.32 Million | ▼ -37.2% |
| 2019 | -0.18x | $-7.44 Million | $41.20 Million | — |